Introduction An altered immune tolerance disturbed by immune checkpoint inhibitors (ICIs)
may contribute to new-onset polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) …

With the aging of the population, malignancies are becoming common complications in
patients with rheumatoid arthritis (RA), particularly in elderly patients. Such malignancies …

Introduction The advent of immune checkpoint inhibitors (ICIs) in cancer treatment has
marked a transformative era, albeit tempered by immune-related adverse events (irAEs) …

Introduction Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease of the
elderly, treated mainly with systemic corticosteroids. The frequency of side effects of steroids …

Background Rheumatic immune-related adverse events (R-irAEs) occur in 5–15% of
patients receiving immune checkpoint inhibitors (ICI) and, unlike other irAEs, tend to be …

Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMR) are a subtype of
rheumatic immune-related adverse event (irAE) arising following immune checkpoint …

Objective To develop recommendations for the routine management of patients with
polymyalgia rheumatica (PMR). Methods Following standard procedures, a systematic …

Background Immune agents targeting Programmed cell death-1 (PD-1) are a new type of
cancer treatment drugs. By inhibiting the interaction between PD-1 and PD-L1, the ability of …

ABSTRACT Background/Purpose Vasculitis as an immune-related adverse event (irAE) from
checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known …

Stakeholders: Collaborators & Partners: refers to those responsible for or affected by
healthcare and healthcare-related decisions. Other terms may include Interested people and …